Merck Video: What the "Great Resignation" Taught Us About Workplace Culture

The global workforce is going through a significant transformation. In 2021, an unprecedented number of workers quit their jobs. What started as an economic trend called the "great resignation" has spurred lasting workplace changes

"It's redefining and recalibrating the relationship between employee and employer, and more specifically, what the employee feels is the employer's responsibility to them," said Steve Pemberton, chief human resources officer, Workhuman.

In episode seven of Teal Talks, Pemberton, along with Karin Kimbrough, chief economist at LinkedIn, and Sarah Kauss, founder of S'well, sits down with Carl Segerstrom, chief talent officer, Merck, to discuss the ongoing changes in the workplace and how businesses can continue to support the growth and development of their employees.

Why are workers quitting their jobs and where are they going?

A Pew Research Center survey found that low pay, a lack of opportunities for advancement and feeling disrespected at work were the top reasons Americans quit their jobs in 2021.

A desire to work from home in remote jobs is also driving some of the turnover in the labor market, Kimbrough said.

"Nearly half of all applicants on our platform apply for at least one remote role. And this is up from an infinitesimally small number pre-pandemic," said Kimbrough. "So, one thing everyone is looking for is that flexibility, and a lot of that comes through remote or hybrid opportunities."

Finding purpose at work

Research has shown that employees want purpose in their professional lives that merges with their personal values.

In a recent survey, more than half of U.S. employees said they'd be willing to take a pay cut to work at a company that shares their values.

Kauss, whose company was founded with a mission to rid the world of single-use plastics, has seen the benefits of this purpose-led mindset.

"I was very surprised by the caliber of employees that were choosing to come to a smaller startup like S'well because of our purpose," Kauss said.

What is "quiet quitting"?

Quiet quitting, the popular term that gained global attention through a viral TikTok video, is when employees stop going above and beyond in their jobs and do the bare minimum. Some experts say quiet quitting is a residual effect of the COVID-19 pandemic, burnout and the "great resignation" because it helped make employees feel empowered to take control of their work-life balance.

"I think what's indicative is whether or not employers are going to meet humans halfway in their recalibration of what work looks like, how it's done, where it's done, and with whom it's done."

-Steve Pemberton

Although many believe the choice of leaving a company may be in the hands of employees during the "great resignation", Kimbrough said LinkedIn data is starting to show a hiring slowdown and an increase in the mention of "layoff" in their feed.

"To some, quiet quitting may mean getting the basic job done, but in these uncertain economic times, quiet quitting can mean lower productivity for the whole company, and it could push employers to let workers go," she said.

The "great resignation's" silver lining

We have arguably seen some of the largest disruptions to the workforce and workplace in decades, but positive developments can be found. "I think the most positive thing that has come out of this time is the increasing emphasis on social issues and how important individuals are to leading great teams and to making positive change in the world," said Kauss.

Learn more about Merck's Environmental, Social & Governance (ESG) approach by visiting merck.com/company-overview/esg.

View original content here

Merck & Co., Inc., Wednesday, December 21, 2022, Press release picture

View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.

Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.merck.com/about/corporate-responsibility/home.html
Email: info@3blmedia.com

SOURCE: Merck & Co., Inc.



View source version on accesswire.com:
https://www.accesswire.com/732750/Merck-Video-What-the-Great-Resignation-Taught-Us-About-Workplace-Culture

News Provided by ACCESSWIRE via QuoteMedia

MRK
The Conversation (0)
Raptor Resources

Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada

Eastern Metals Ltd (ASX: EMS) (Eastern Metals or the Company) (to be renamed Raptor Metals Ltd (ASX: RAP)) is pleased to advise it has recommenced trading on the Australian Securities Exchange (ASX) today following its acquisition of Raptor Resources Limited (Raptor Resources). HIGHLIGHTS... Keep Reading...
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News